Ineffective treatments are still common in the health service, creating unnecessary suffering for patients and high costs for society. With an ageing population and increasing pressure on the health services, this challenge is becoming increasingly important.
To find more accurate and personalized treatments, SINTEF develops functional precision medicine in collaboration with clinical and academic partners: cells from patient biopsies are cultured and tested in the laboratory using highly automated and advanced state-of-the-art laboratory facilities.
In our laboratories, SINTEF combines advanced testing of patient-derived samples, automated functional screening, biomarker discovery, and prospective clinical implementation within a unique, leading, single translational precision medicine platform.
The results from such experiments are used to select the treatment that is most likely to work for the individual patient, or to better understand the disease.
• SINTEF is among the first in the world to implement this approach in the clinic through the ongoing COSENSE-1 study (EUCT: 2024-517677-25-00), in collaboration with local clinical and academic partners.
• This is a prospective trial for the selection for first-line chemotherapy, where SINTEF provides functional drug sensitivity testing results within one week, which is a sufficiently fast turn-around time to be used clinically.
Experience across disease areas
• Colorectal cancer
• Endometriosis
• Inflammatory bowel disease
• Bile duct cancer
• Colon organoids
• Kidney organoids.
We work within these areas
• Developing cultivation methods for primary patient materials
• Functional testing of drugs on primary patient tissue.
• Clinical trials using patient-derived functional assays for clinical decision support
• Highly automated, high-throughput and high-content characterization of drug effects.
Methods and technologies
• Primary patient-derived cell culture
• High-throughput drug sensitivity testing
• Automated high-content imaging
• Cell Painting for patient-derived cells in 2D and 3D.
• Samples for histochemical characterization, single cell, and -omics analyses
• High-throughput drug combination testing
• Multi-omics and biomarker discovery
How SINTEF adds value
• SINTEF has a proven 10-year experience establishing functional assays from patient-derived tissues.
• Advanced automation enables robust, scalable, and reproducible methods
• For academics, SINTEF can perform ex vivo analyses for advanced phenotypic characterization, multi-omic screening, biomarker discovery, and testing of experimental drugs.
• For clinicians, SINTEF enables functional testing of therapies in patient-derived samples in a clinically relevant time frame.
• For pharma industry, SINTEF provides clinically relevant functional assays for biomarker discovery, patient stratification, companion diagnostics, and drug development.
Relevant laboratories og research areas
- High-throughput screening
- Mass spectrometry
- Nanomedisin
- Cell- and microbiology
- Biomass and biomaterials
Projects
- COSENSE/PRESORT
Publications:
• High-content morphological profiling by Cell Painting in 3D spheroids.
Ringers C, Holmberg D, Larsson A, Jung B, Jarvius M, Luchniak A, Rosén D, Johansson M, Georgiev P, Seashore-Ludlow B, Visnes T, Flobak Å, Carreras-Puigvert J, Spjuth O. Nat Commun. 2026 Oct 21;17(1):10790. doi: 10.1038/s41467-026-78596-5. PMID: 42907469.
• A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics. Sakshaug BC, Haukaas TH, Folkesson E, Ringers C, Bwanika HCH, Bergstrøm IA, Sigfúsdóttir MS, Trøen HH, Sperstad SB, Stornes T, Klinkenberg G, Visnes T, Flobak.